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Objectives: Impaired social, role, and neurocognitive func-
tioning are preillness characteristics of people who later 
develop psychosis. In people with schizophrenia, neurocogni-
tion and negative symptoms are associated with functional 
impairment. We examined the relative contributions of neu-
rocognition and symptoms to social and role functioning over 
time in clinically high-risk (CHR) individuals and determined 
if negative symptoms mediated the influence of cognition on 
functioning. Methods: Social, role, and neurocognitive func-
tioning and positive, negative, and disorganized symptoms 
were assessed in 167 individuals at CHR for psychosis in 
the North American Prodrome Longitudinal Study Phase 
1 (NAPLS-1), of whom 96 were reassessed at 12 months. 
Results: Regression analyses indicated that negative symp-
toms accounted for unique variance in social and role func-
tioning at baseline and follow-up. Composite neurocognition 
accounted for unique, but modest, variance in social and role 
functioning at baseline and in role functioning at follow-
up. Negative symptoms mediated the relationship between 
composite neurocognition and social and role functioning 
across time points. In exploratory analyses, individual tests 
(IQ estimate, Digit Symbol/Coding, verbal memory) selec-
tively accounted for social and role functioning at baseline 
and follow-up after accounting for symptoms. When nega-
tive symptom items with content overlapping with social and 
role functioning measures were removed, the relationship 
between neurocognition and social and role functioning was 
strengthened. Conclusion: The modest overlap among neuro-
cognition, negative symptoms, and social and role function-
ing indicates that these domains make substantially separate 
contributions to CHR individuals.
Key words: social and role functioning/neurocognition/ 
negative symptoms/prodrome
The search for robust clinical indicators of psychosis and 
associated disability has accelerated with the gradual accep-
tance of the clinical high-risk (CHR) phase prior to psycho-
sis (“putative prodrome”).1–3 In the neurodevelopmental 
model proposed by Cornblatt and colleagues,4 psychosis 
vulnerability involves deficits in at least 4 clinically mea-
sureable domains (Cognitive-Affective-Social Isolation-
School/work problems) referred to as the “CASIS” cluster 
that are thought to develop relatively independently of pos-
itive symptoms. There is substantial support for this model 
in that neurocognitive and functional (eg, impaired social 
and role functioning) deficits are present prior to and dur-
ing the CHR phase.4–9 Greater neurocognitive impairments 
prospectively predict conversion to psychosis among CHR 
participants.6,10,11 Negative symptoms predict transition to 
psychosis among people at CHR.1,12 Social difficulties also 
predict conversion among people at CHR after accounting 
for attenuated positive symptoms.1–3 Impairment in social 
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and role functioning is a central aspect of the persistent dif-
ficulties experienced by many people at CHR, regardless 
of whether they transition to psychosis.5,13–15 Our goal is to 
focus on an understudied area in CHR research: the relative 
contributions of neurocognition and symptoms to func-
tional outcomes over time in CHR participants, including 
whether negative symptoms mediate the impact of neuro-
cognition on social and role functioning in CHR, based on 
the schizophrenia literature.16
The notion that domains of neurocognitive impairment 
are related to social or role impairment in schizophrenia 
was first demonstrated by Green and colleagues, initially 
in chronic schizophrenia samples.17 More recent research 
supports the relationship between neurocognition and 
functional outcomes in recent-onset psychosis.18–21 
A  meta-analysis found that negative symptoms were 
associated with functional outcomes in schizophrenia, in 
contrast to the negligible relationship between positive 
symptoms and functional outcomes.16 Negative symptoms 
also prospectively predicted functioning in first-episode 
schizophrenia.22 While prior findings suggest that neuro-
cognition may be a stronger predictor of functioning than 
symptoms in schizophrenia,23,24 some have questioned 
the extent to which neurocognition predicts functioning 
independent of symptoms.25,26 In chronic and first-episode 
schizophrenia, negative symptoms are moderately associ-
ated with neurocognition,16,27–32 with smaller associations 
between disorganized symptoms and cognition,31–34 and 
weak relationships between positive symptoms and neu-
rocognition.16,29 Thus, the joint impact of negative symp-
toms and neurocognition on function requires more study, 
particularly in longitudinal CHR studies.16
Several studies examined some relations among these 
constructs in CHR samples. In a small study of 22 par-
ticipants, baseline disorganized symptoms and execu-
tive functioning deficits predicted self-reported social 
functioning at 1-year follow-up, and baseline deficits in 
executive functioning and processing speed predicted self-
reported work functioning at follow-up.35 By contrast, in 
a study of 35 participants, neither baseline neurocogni-
tive functioning nor clinical symptoms predicted social or 
role functioning at 8 months.36 In a large study of 230 par-
ticipants with an average follow-up duration of 7 years, 
baseline negative symptoms and poor verbal memory pre-
dicted poor functional outcomes at follow-up.13 Tests of 
processing speed and verbal fluency also emerged as pro-
spective predictors of poor functioning in subsamples of 
participants. In another study, social and role functioning 
deficits were associated with worse processing speed and 
global neurocognition at baseline.37 These findings were 
independent of positive symptoms, although negative and 
disorganized symptoms were not examined. At 3-year 
follow-up with this sample, disorganized symptoms and 
worse processing speed predicted impaired social func-
tioning, while disorganized symptoms and motor distur-
bances predicted impaired role functioning.38
In the current study, we examined the contributions of 
symptoms and a composite neurocognition score to social 
and role functioning at baseline and 12-month follow-
up among CHR individuals from the North American 
Prodrome Longitudinal Study Phase 1 (NAPLS-1). 
We hypothesized that (1) negative symptoms would be 
more strongly associated with social and role function-
ing than positive or disorganized symptoms, (2) negative 
symptoms and neurocognition would each account for 
unique variance in social and role functioning at base-
line, (3) baseline composite neurocognition and negative 
symptoms would each independently predict social and 
role functioning at 12-month follow-up, and (4) negative 
symptoms would mediate the relationship between neu-
rocognition and social and role functioning at baseline 
and at 12 months. Based on prior research,13,18,32,36,37 we 
explored whether certain individual neurocognitive tests 
(IQ, processing speed, verbal memory) accounted for 
social and role functioning cross-sectionally and at 12 
months after controlling for baseline symptoms.
Methods
Study protocols and informed consent documents, 
including procedures, were approved by the Institutional 
Review Boards of the 8 participating sites. NAPLS-1 
methods and details of the federated database are 
described elsewhere.3,6
Sample
The NAPLS-1 CHR sample consisted of 370 individuals 
who met the Criteria of Prodromal Syndromes (COPS), 
based on the Structured Interview for Prodromal 
Syndromes (SIPS),39 of whom 35% converted to psycho-
sis over 30 months.3 The participants ranged from 12 to 
36 years of age and had IQs of at least 70. The current 
sample is the identical subsample (n = 167) who com-
pleted a minimum of 75% of the most commonly admin-
istered neurocognitive tests in the NAPLS-1 federated 
baseline database (ie, 6 or more of 8 tests) and for whom 
a composite cognition score was computed.6 That report,6 
which details the neurocognitive methodology, indicated 
that this subsample did not differ on any demographic 
characteristic from the larger NAPLS-1 CHR sample. 
We conducted additional T tests indicating that this sub-
sample was not significantly different from the remaining 
NAPLS-1 sample in baseline social or role functioning or 
in positive, negative, or disorganized symptoms (P values 
> .21). About one-third of this subsample was included 
in a prior NAPLS-1 study examining predictors of social 
and role functioning,5 although that article did not focus 
on neurocognition or address the relationship between 
neurocognition and negative symptoms in predicting 
functioning, and 23% overlap with another recently pub-
lished study.38 Of the 167 participants included here, 96 
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and 94 completed the measure of social and role func-
tioning at 12-month follow-up, respectively.
Measures
CHR Status and Clinical Symptoms. The SIPS criteria39 
was used for study entry. About 97% of CHR individu-
als met full criteria for Attenuated Positive Symptom 
(APS) Syndrome, which emphasizes onset or worsening 
of attenuated positive symptoms in the past 12 months, in 
at least one of the 5 positive symptom domains: unusual 
thought content, suspiciousness/paranoia, grandiosity, 
perceptual anomalies, and conceptual disorganization. 
In addition to attenuated positive symptoms (SIPS-
Positive), we assessed SIPS-Negative (social anhedonia or 
withdrawal, avolition, decreased expression of emotions, 
decreased experience of emotions and self, decreased ide-
ational richness, deterioration in role functioning) and 
SIPS-Disorganized (odd behavior or appearance, bizarre 
thinking, trouble with focus and attention, personal 
hygiene/social attentiveness). Symptom domain scores 
are the sum of symptom severity scores.
Social and Role Functioning. Social and role functioning 
was assessed using the GF: Social and GF: Role scales.40 
These rater-scored measures were designed as parallel, 
well-anchored scales that account for age and phase of ill-
ness and detect functional changes over time.40 GF: Social 
assesses peer relationships, peer conflict, age appropri-
ate intimate relationships, and involvement with family 
members. GF: Role assesses performance and amount of 
support needed in one’s specific roles (ie, school/work). 
Scores range from 1 to 10 (10 = superior functioning to 1 
= extreme dysfunction). Scores around 6 typically charac-
terize CHR individuals.40 Current (ie, past month) scores 
were used in the current study. In NAPLS-1, ratings for 
each scale were based on best estimates derived from all 
available information.40 This approach has been used in 
prior reports3,5,15 and exhibited high interrater reliability.2
Neurocognitive Assessment. The tests and domains 
included were as follows: verbal comprehension 
(Vocabulary), visual-perceptual-organization (Block 
Design), vigilance (Continuous Performance Test-
Identical Pairs Version), processing speed (Digit Symbol/
Coding), executive functioning including verbal fluency 
(Controlled Oral Word Association test [COWA]) and 
problem solving (Wisconsin Card Sorting Test [WCST] 
perseverative errors), and a verbal memory composite 
score. These tests are representative of those sensitive 
to impairments in CHR individuals.10,11 A small propor-
tion (7.3%) of the test scores were missing. A composite 
neurocognition score was constructed as the standard-
ized mean of the test scores. For the exploratory analyses 
examining individual test scores, we examined Full Scale 
IQ (FSIQ) estimates. Additional detail regarding the 
tests, missing data, and computation of the composite 
score can be found in table 3, in an online supplementary 
data, and in a prior report.6
Statistical Analyses
Statistical analyses were performed using IBM SPSS 
version 20. Preliminary between-groups analyses were 
conducted to examine the comparability of participants 
who completed GF: Social and GF: Role at 12-month 
follow-up with those who did not. Correlational analy-
ses were conducted to examine the relations among cog-
nitive tests, SIPS symptoms, GF: Social, and GF: Role. 
Simultaneous regression analyses were conducted to test 
the hypotheses that (1) SIPS-Negative symptoms would 
be more strongly associated with GF: Social and GF: 
Role than SIPS-Positive or SIPS-Disorganized, (2) SIPS-
Negative and composite cognition would independently 
account for unique variance in GF: Social and GF: Role 
cross-sectionally, and (3) baseline SIPS-Negative and 
composite cognition would independently predict GF: 
Social and GF: Role at 12-month follow-up. We exam-
ined the influence of content overlap between SIPS-
Negative and the functioning measures by rerunning the 
primary regression models after removing overlapping 
items. Specifically, we reran the models predicting GF: 
Social after removing the SIPS-Negative item tapping 
social anhedonia or withdrawal and the models predict-
ing GF: Role after removing the item tapping deteriora-
tion in role functioning. Next, we tested the hypothesis 
that SIPS-Negative would mediate the relations between 
cognition and GF: Social and GF: Role at baseline and 
follow-up using Sobel tests. Finally, we explored whether 
selected cognitive tests (FSIQ estimate, Digit Symbol/
Coding, verbal memory) accounted for GF: Social and 
GF: Role at baseline and follow-up, controlling for symp-
toms, using simultaneous regressions.
Results
Primary Analyses
Participant characteristics are listed in table 1. Participants 
who completed GF: Social and GF: Role at 12-month 
follow-up did not differ from those who did not on base-
line functioning (table 2). A paired-sample t-test indicated 
that GF: Social improved at 12 months in the follow-up 
sample, t(95) = 3.15, P = .002 as did GF: Role, t(93) = 
4.60, P < .001. T tests indicated that the follow-up sam-
ple did not differ from the rest of the sample on baseline 
composite neurocognition or any SIPS symptom domain 
(P values = .11–.52).
Pearson product-moment correlations among the neu-
rocognitive tests, SIPS symptom domains, GF: Social, 
and GF: Role are presented in table 3. Among the symp-
tom domains, SIPS-Negative was most strongly associ-
ated with neurocognition, though the correlations were 
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modest, followed by SIPS-Disorganized. SIPS-Positive 
was only marginally associated with one cognitive test 
and was not associated with the composite score. All 
neurocognitive tests were modestly associated with GF: 
Social at baseline. Most neurocognitive tests were mod-
estly associated with GF: Social at follow-up, with the 
exception of Block Design and COWA. Similarly, most 
neurocognitive tests were modestly associated with GF: 
Role at baseline and follow-up, with the exception of 
Block Design at both time points and COWA at follow-
up. SIPS-Negative was most strongly associated with GF: 
Social and GF: Role at baseline and follow-up, followed 
by SIPS-Disorganized. SIPS-Positive was not associated 
with GF: Social or GF: Role at either time point. GF: 
Social was moderately associated with GF: Role at base-
line, and this association became stronger at follow-up. 
The test-retest reliability coefficients were .69 for GF: 
Social and .50 for GF: Role.
All variables included in regression analyses were nor-
mally distributed. Simultaneous regression analyses were 
conducted in which baseline SIPS symptom clusters and 
composite cognition score were entered as predictors, and 
GF: Social and GF: Role at baseline and follow-up were 
the outcomes (table 4). At baseline, both models were sig-
nificant, accounting for 36% of the variance in GF: Social 
and 35% of the variance in GF: Role. SIPS-Negative was 
most strongly associated with functioning at both time 
points. SIPS-Negative (β = −.390; P < .001) and compos-
ite neurocognition (β = .175; P = .013) each accounted 
for unique variance in GF: Social at baseline. Similarly, 
both SIPS-Negative (β = −.413; P < .001) and compos-
ite neurocognition (β = .153; P = .036) were associated 
with GF: Role at baseline. At follow-up, both models were 
again significant, accounting for 32% of the variance in 
GF: Social and 25% of the variance in GF: Role. SIPS-
Negative (β = −.447; P < .001) was the only significant 
predictor of GF: Social at follow-up. Both SIPS-Negative 
(β = −.398; P = .002) and composite neurocognition (β = 
.232; P = .028) were significant predictors of GF: Role at 
follow-up. Neither SIPS-Disorganized nor SIPS-Positive 
were associated with social or role functioning at either 
time point.
Modified Analyses After Removing Select Negative 
Symptom Items
We examined the influence of content overlap in assess-
ing the relationship between negative symptoms and func-
tioning (table 5). The models predicting GF: Social and 
GF: Role at baseline and follow-up remained significant 
(all P values remained <.001), though the amount of vari-
ance in functioning explained by these models (ie, total R2) 
decreased by 17% on average. The magnitude of the asso-
ciations between SIPS-Negative and functioning (ie, stan-
dardized regression coefficients) decreased in each case by 
an average of 40%. Conversely, the magnitude of the rela-
tions between composite neurocognition and functioning 
and SIPS-Disorganized and functioning increased by an 
average of 21% and 34%, respectively. When the over-
lapping symptoms were removed from SIPS-Negative, 
the magnitude of the associations between composite 
Table 1. Participant Characteristics
M SD
Age (y) 18.2 4.9
Education (y) 10.4 3.1
Parental educationa 5.4 1.6
n %
Male gender 107 64.1
Taking antipsychotic medication 6 3.6
White race 139 83.2
African American race 15 9.0
Asian American 6 3.6
Multiracial 7 4.2
Hispanic ethnicity 23 13.8
Note: aParental education was assessed on the following scale: 
1 (less than high school); 2 (some high school); 3 (high school 
graduate); 4 (some college); 5 (associate’s degree); 6 (bachelor’s 
degree); 7 (some postgraduate education); and 8 (graduate degree).
Table 2. Social and Role Functioning Scores by Follow-up Status
Participants Who Completed 
Measures at Follow-up
Participants Who Did Not  
Complete Follow-up Measures
Test  
Statistic (t)M SD M SD
GF: Social (baseline) 6.40 1.7 5.95 1.4 1.81
GF: Social (follow-up) 6.82 1.6 — — —
GF: Role (baseline) 6.26 1.8 6.11 1.5 0.56
GF: Role (follow-up) 7.04 1.5 — — —
Note: GF: Social, Global Social Functioning Scale; GF: Role, Global Role Functioning Scale. Follow-up n for GF: Social = 96. 
Follow-up n for GF: Role = 94.
*P < .05, **P < .01, ***P < .001 (none were significant).
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neurocognition and/or SIPS-Disorganized and function-
ing were roughly equivalent to those of SIPS-Negative.
Mediation Analyses
We used Sobel tests41 to examine whether SIPS-Negative 
mediated the relations between composite neurocogni-
tion and GF: Social and GF: Role at baseline and fol-
low-up. Evidence for mediation would be observed if: 
(1) composite neurocognition significantly affects SIPS-
Negative, (2) neurocognition significantly affects GF: 
Social and GF: Role in the absence of SIPS-Negative, (3) 
SIPS-Negative has a significant, unique effect on func-
tioning, and (4) the effect of neurocognition on function-
ing shrinks when SIPS-Negative is added to the model. 
A  significant result with the Sobel test is evidence of 
partial mediation and does not make any claim regard-
ing full mediation. In each case, the Sobel test was highly 
significant (test values ranged from 2.98 to 4.14; P values 
from .003 to <.001), indicating that SIPS-Negative medi-
ated the relations between cognition and GF: Social and 
GF: Role at baseline and follow-up. Removing the respec-
tive overlapping symptoms yielded the same finding that 
SIPS-Negative mediated the effects of cognition on GF: 
Social and GF: Role at baseline and follow-up (Sobel test 
values = 2.59–3.72; P values = .01 to <.001).
Exploratory Analyses Using Individual Tests
We explored whether selected individual baseline neuro-
cognitive tests accounted for GF: Social and GF: Role, 
controlling for symptoms, at baseline and follow-up using 
simultaneous regression analyses (supplementary tables 
S1a–S3a). SIPS symptom domains were entered into 
each regression model, along with FSIQ estimate, Digit 
Symbol/Coding, and verbal memory in separate models. 
All models were significant and accounted for approxi-
mately the same amount of variance in functioning as the 
primary regressions that included the composite neurocog-
nition score. Both IQ estimate and Digit Symbol/Coding 
accounted for unique variance in GF: Social at baseline 
only (β = .164, P = .013 and β = .141, P = .048, respec-
tively) and did not account for unique variance in GF: 
Role at either time point. Verbal memory did not account 
for GF: Social or GF: Role at baseline but did predict GF: 
Role at follow-up (β = .218, P = .040). Removing the over-
lapping items from SIPS-Negative increased the magni-
tude of the relations between these individual cognitive 
tests and functioning (supplementary tables S1b–S3b). 
Specifically, IQ estimate continued to account for unique 
variance in GF: Social (β = .18, P = .01) and became 
significant for GF: Role at baseline (β = .16, P = .026). 
Digit Symbol/Coding continued to account for unique 
Table 4. Regression Analyses Examining Predictors of Social and Role Functioning at Baseline and 12-Month Follow-up
Baseline Predictor
GF: Social (Baseline) GF: Social (Follow-up) GF: Role (Baseline) GF: Role (Follow-up)
β β β β
SIPS-Positive −.037 .136 .024 −.067
SIPS-Negative −.390*** −.447*** −.413*** −.398**
SIPS-Disorganized −.166 −.134 −.117 .055
Composite cognition .175* .085 .153* .232*
Total R2 .363*** .345*** .318*** .253***
Note: β, standardized regression coefficients. Abbreviations are explained in the first footnote to tables 2 and 3.
*P < .05, **P < .01, ***P < .001.
Table 5. Regression Analyses Examining Predictors of Social and Role Functioning at Baseline and 12-Month Follow-up After 
Removing Negative Symptoms That Overlap With Functioning
Baseline Predictor
GF: Social (Baseline) GF: Social (Follow-up) GF: Role (Baseline) GF: Role (Follow-up)
β β β β
SIPS-Positive −.027 .150 .043 −.056
SIPS-Negative −.207* −.246* −.221* −.314*
SIPS-Disorganized −.283** −.263* −.238* −.004
Composite cognition .214** .123 .208** .259*
Total R2 .305*** .272*** .254*** .227***
Note: β, standardized regression coefficients. Abbreviations are explained in the first footnote to tables 2 and 3. The SIPS-Negative item 
tapping social anhedonia or withdrawal was removed from analyses of GF: Social. The SIPS-Negative item tapping deterioration in role 
functioning was removed from analyses of GF: Role.
*P < .05, **P < .01, ***P < .001.
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variance in GF: Social at baseline (β = .188, P = .011) and 
became a significant predictor of GF: Social at follow-up 
 (β = .193, P = .049) and of GF: Role at baseline (β = .201, 
P = .008). Verbal memory became significant for GF: 
Social at baseline (β = .171, P = .024) and continued to 
predict GF: Role at follow-up (β = .233, P = .032).
Discussion
The results of the primary analyses generally supported 
our hypotheses and shed new light on the relationship 
of neurocognition and negative symptoms in CHR 
individuals. First, the findings are generally consistent 
with research on chronic and first-episode schizophre-
nia studies in terms of the influence of neurocognition 
and symptoms on functioning. In baseline correlational 
analyses, worse performance on neurocognitive tests and 
composite neurocognition was most strongly associated 
with negative symptom severity, followed by disorganized 
symptom severity, whereas positive symptoms were not 
meaningfully associated with neurocognition. As hypoth-
esized, in regression analyses, we found that negative 
symptoms were associated with social and role function-
ing at both time points, whereas neither positive nor dis-
organized symptoms accounted for unique variance in 
functioning at either time point. This finding is consistent 
with most prior research in CHR13 and schizophrenia16 
samples, although few prior studies examined disorga-
nized symptoms. Next, as hypothesized, we found that 
composite neurocognition accounted for unique variance 
in social and role functioning at baseline after accounting 
for symptoms. We found partial support for our hypoth-
esis regarding the prospective analyses, as baseline com-
posite neurocognition accounted for unique variance in 
role, but not social functioning at 12-month follow-up 
after accounting for baseline symptoms. In the primary 
analyses, negative symptoms were the strongest predictor 
of social and role functioning at baseline and 12-month 
follow-up and had small-to-medium effects, followed by 
composite neurocognition, which had small independent 
effects. In exploratory analyses, individual tests (IQ esti-
mate, Digit Symbol/Coding, verbal memory) selectively 
accounted for functioning at baseline and follow-up after 
accounting for symptoms, which is consistent with prior 
CHR studies.13,35,38 Finally, negative symptoms did indeed 
mediate the relationship between neurocognition and 
social and role functioning at both time points.
An important methodological issue was noted in these 
analyses. That is, 2 items in the SIPS negative symptom 
scale overlap with one item each on the social and role 
functioning scales. Specifically, the SIPS-Negative scale 
contains 2 symptoms, “social anhedonia or withdrawal” 
and “deterioration in role functioning” that overlap with 
social and role functioning, respectively. When these 
overlapping items were removed, the magnitude of the 
relationship between negative symptoms and functioning 
was reduced substantially. Conversely, the magnitude 
of the relations between composite neurocognition and 
functioning and between disorganized symptoms and 
functioning both increased substantially and became 
roughly equivalent to the relationship between negative 
symptoms and functioning. These supplementary find-
ings with respect to disorganized symptoms are consistent 
with 2 prior CHR studies that found that disorganized 
symptoms, not positive or negative symptoms, prospec-
tively predicted functional outcomes.35,38 This conver-
gence in findings, in part, could be due to some small 
overlap (23%) between the current sample and one of the 
prior studies.38 Removing the overlapping items resulted 
in Digit Symbol/Coding becoming a significant predic-
tor of 12-month social functioning. Item overlap did not 
influence the findings regarding negative symptoms as 
a mediator of the relationship between composite neu-
rocognition and functioning. Further complicating this 
issue with respect to the SIPS-Negative scale is that the 
item tapping “social anhedonia or withdrawal” may be 
viewed as combining a symptom (anhedonia) with an 
aspect of functioning (withdrawal). This issue warrants 
increased attention in future investigations of the rela-
tionship between negative symptoms and functional 
outcomes.
Negative symptoms mediated the relationship between 
composite neurocognition and social and role function-
ing both at baseline and at 12-month follow-up. This rep-
licates the findings of a meta-analysis of schizophrenia 
studies16 and extends the finding to CHR participants. 
Moreover, the current study was the first to examine 
mediation longitudinally in CHR participants, which is 
important for validating this relationship between neuro-
cognition and negative symptoms as it relates to function-
ing. As noted previously,16 the designation of cognition as 
the predictor (IV) and negative symptoms as the media-
tor may be viewed as somewhat arbitrary. To support 
this approach, we relied on theory, evidence document-
ing early premorbid cognitive deficits in those who even-
tually develop psychosis,7,9 and lack of strong evidence 
suggesting that negative symptoms cause neurocognitive 
deficits. The finding that negative symptoms mediated 
the effect of neurocognition on social and role function-
ing across time has implications for treatment with CHR 
individuals. Overall, these findings support the rationale 
for integrative psychosocial rehabilitation programs for 
early psychosis that target both negative symptoms and 
neurocognition as a means of improving functioning.
The observation of a more modest relationship between 
neurocognition and functioning in CHR samples than in 
schizophrenia42 is important. This may suggest, in part, 
that the CHR syndrome reflects a changing phase of ill-
ness in which some individuals go on to develop psychosis 
(and not all schizophrenia), others remain somewhat sta-
bly impaired, and a third subgroup improves.15 This con-
trasts with the relative stability of samples of patients with 
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schizophrenia in which both neurocognition and social and 
role impairments are more likely to be stable. Moreover, 
neurocognitive impairments among CHR individuals as a 
whole, compared to converters, are relatively mild6 and may 
have a weaker impact on functioning. The contribution of 
neurocognition was somewhat stronger for role, compared 
to social functioning, over time. In both the primary analy-
ses and the analyses adjusting for overlapping symptoms, 
the magnitude of the relationship between neurocognition 
and role functioning increased slightly over time, whereas 
the relationship between neurocognition and social func-
tioning decreased and became nonsignificant at follow-up. 
The aspects of neurocognitive functioning (memory, atten-
tion, processing speed, and so forth) assessed in this study 
may have greater independent associations with role func-
tions such as school or job-related tasks over time than with 
social functioning. Social cognition, which was not assessed 
in this study, appears to be more strongly associated with 
social functioning over time.43
The current findings should be interpreted in the 
context of  several limitations. First, because NAPLS-1 
participants were drawn from different studies and 
combined in a federated database, the full complement 
of  measures administered in these studies could not be 
used. This was particularly true for neurocognitive mea-
sures, as only a modest subset was given across sites.6 In 
particular, the verbal memory measure was an amalgam 
of different measures. Nevertheless, these measures are 
typical of  those given in other studies and represent a 
reasonable assessment of  neurocognitive functioning 
in the prodrome.10,11 Of the tests included, the rate of 
missing test scores was low. Second, this study used a 
set of  common clinical neuropsychological tests, most 
of  which tap multiple aspects of  cognition, and in the-
ory they may not be optimal for elucidating relations 
among symptoms, cognition, and functioning. In terms 
of  future directions, it may be more likely that studies 
linking social cognition43 and more specific aspects of 
cognition (ie, a cognitive neuroscience approach)44 will 
elucidate relations with specific symptoms and aspects 
of  functioning. Next, while the sample was reasonably 
large, only a subset completed the functioning measures 
at follow-up. Future research, including NAPLS-2,45 can 
address these issues with a larger sample and a more 
sophisticated neurocognitive battery. Next, in addition 
to content overlap, method variance may have influenced 
the relations between symptoms and functioning, as the 
same raters used clinical judgment in assessing both con-
structs. Multimethod approaches to assessing function-
ing are recommended for use in future research, including 
performance-based or functional capacity measures46 
and measures of  motivation.47 Exploring mediators 
and mechanisms of  action in integrative rehabilitation 
programs may also be helpful by clarifying whether, for 
example, such programs improve functioning by modi-
fying aspects of  neurocognition or by reducing negative 
symptoms. Individual participant predictor models can 
be tested and likely enhanced by the joint use of  neuro-
cognition, social and role functioning, and symptoms, all 
of  which are sufficiently independent to warrant inclu-
sion in multivariate prediction models. Finally, given 
that initial meta-analyses of  treatment of  CHR individu-
als are promising,48 it is possible that a new generation of 
specific treatments designed to improve neurocognition 
and negative and disorganized symptoms will further 
improve the lives of  CHR individuals.
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